Intranasal glucagon appears to represent a major breakthrough in the treatment of severe hypoglycemia in insulin-treated patients with diabetes, both children and adults [58,59], as it represents a more effective route of administration for caregivers that face the challenge of dealing with the stress of an episode of SH. This evidence concerns the gene INS and diabetes mellitus.